Italia markets open in 6 hours 36 minutes

Kala Pharmaceuticals, Inc. (0JQ2.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,3380+0,0252 (+8,06%)
Alla chiusura: 03:20PM BST
Schermo intero
Chiusura precedente0,3128
Aperto0,3400
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,3374 - 0,3400
Intervallo di 52 settimane0,3374 - 0,3400
Volume23.703
Media VolumeN/D
Capitalizzazione78.841
Beta (5 anni mensile)1,03
Rapporto PE (ttm)N/D
EPS (ttm)-2,1370
Prossima data utili11 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call

    ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-i

  • GlobeNewswire

    Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

    ARLINGTON, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in August 2022: 2022 Wedbush PacGrow Healthcare ConferenceDate: Wednesday, August 10, 2022Company management will participate in a fireside ch

  • GlobeNewswire

    Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    ARLINGTON, Mass., July 22, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 40,000 shares of Kala Pharmaceuticals common stock to the new employee. The stock options were granted on July 18, 2022. The gra